
Investments
2Portfolio Exits
4Partners & Customers
10
Want to inform investors similar to University Health Network about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest University Health Network News
Sep 20, 2023
TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids). The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations collaborate in a proactive manner to identify disruptive technologies derived from transformational discovery research conducted by the scientific community of Toronto. TIAP has reviewed dozens of projects from its membership and together with the partnership’s joint steering committee has identified three projects – two therapeutic projects and one platform validation project – for further investment. For the Toronto-based academic research community, the partnership enables early engagement and mentorship by corporate drug discovery experts and opportunities for follow-on support and company creation. The first slate of partnered projects, now underway, represents over $1 million in direct investment. In addition to the capital provided by TIAP and Amgen, each project has dedicated scientific and business expertise from Amgen and TIAP to ensure projects are hitting milestones and have appropriate expertise to support development and ultimately availability and distribution. The first approved project is in partnership with Dr. Robert Rottapel, Senior Scientist at the Princess Margaret Cancer Centre at UHN. The project is focused on developing monoclonal antibodies against a novel target for the treatment of drug-resistant ovarian cancers. In addition, this project has also secured financial support from UHN’s Princess Margaret Cancer Centre Innovation Acceleration Fund (IAF). Next is a therapeutic approach in the cardiovascular space, led by co-principal investigators Drs. John Coles and Jason Maynes from SickKids. This drug discovery effort, conducted in collaboration with Evotec through the LAB150 program, is aimed at developing a first-in-class molecule with envisioned applications in heart failure and cardiac fibrosis. Finally, the most recently approved project is a collaborative effort between Amgen’s Expression and Cell Engineering group and the laboratory of Dr. Shana Kelley, Professor at the University of Toronto. The project leverages the proprietary Microfluidics Immunomagnetic Cell Sorting Device developed by Dr. Kelley’s laboratory, with the aim of substantially boosting the yields of cell-grown biologic products. Said Parimal Nathwani, President and CEO of TIAP, “It is hugely significant for TIAP and the local health sciences community to work with an important partner such as Amgen. This partnership has already proven its merit by identifying and funding projects in less than a year in areas with large unmet medical needs and by supporting their accelerated progress and funding. With Amgen’s strong engagement, these projects are well positioned to advance through the critical early stages of development and move towards a path for venture creation” According to Phil Tagari, Vice President of Research at Amgen, “TIAP provides a unique and highly curated vehicle for Amgen’s scientists to access and support cutting-edge biomedical research in one of the world’s foremost centers of innovation and excellence. TIAP very efficiently enabled the identification and funding of the first three opportunities which span diverse areas of interest to Amgen Inc.” For more information, please contact Susanne Staer at sstaer@tiap.ca.
University Health Network Investments
2 Investments
University Health Network has made 2 investments. Their latest investment was in SQI Diagnostics as part of their Grant on March 3, 2020.

University Health Network Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/25/2020 | Grant | SQI Diagnostics | Yes | 1 | ||
10/11/2011 | Seed VC |
Date | 3/25/2020 | 10/11/2011 |
---|---|---|
Round | Grant | Seed VC |
Company | SQI Diagnostics | |
Amount | ||
New? | Yes | |
Co-Investors | ||
Sources | 1 |
University Health Network Portfolio Exits
4 Portfolio Exits
University Health Network has 4 portfolio exits. Their latest portfolio exit was Adela on January 01, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/1/2020 | Spinoff / Spinout | Adela | 1 | ||
Date | 1/1/2020 | |||
---|---|---|---|---|
Exit | Spinoff / Spinout | |||
Companies | Adela | |||
Valuation | ||||
Acquirer | ||||
Sources | 1 |
University Health Network Acquisitions
1 Acquisition
University Health Network acquired 1 company. Their latest acquisition was Surgery Center of Columbia County on January 28, 2020.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
1/28/2020 | Corporate Majority | 1 |
Date | 1/28/2020 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Corporate Majority |
Sources | 1 |
University Health Network Partners & Customers
10 Partners and customers
University Health Network has 10 strategic partners and customers. University Health Network recently partnered with Providence Therapeutics on June 6, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
6/2/2023 | Partner | Canada | Brad Wouters , Executive Vice President , Science and Research at the University Health Network added , `` Our partnership with Providence Therapeutics demonstrates the strength of discovery research at the University Health Network and our potential to fuel innovative therapeutic options for patients . | 5 | |
2/24/2023 | Partner | Canada, and | We are so pleased to announce this historic partnership between Toronto Public Health , Unity Health Toronto and University Health Network , with all of us working together in response to the ongoing drug poisoning crisis . '' | 1 | |
1/12/2023 | Client, and Vendor | Canada | `` As one of our four projects with OBIO , the partnership with Gray Oncology Solutions Inc. is an opportunity to use innovation to help elevate and streamline how we deliver care to our patients . '' | 1 | |
12/7/2022 | Vendor | ||||
9/8/2022 | Vendor |
Date | 6/2/2023 | 2/24/2023 | 1/12/2023 | 12/7/2022 | 9/8/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Client, and Vendor | Vendor | Vendor |
Business Partner | |||||
Country | Canada | Canada, and | Canada | ||
News Snippet | Brad Wouters , Executive Vice President , Science and Research at the University Health Network added , `` Our partnership with Providence Therapeutics demonstrates the strength of discovery research at the University Health Network and our potential to fuel innovative therapeutic options for patients . | We are so pleased to announce this historic partnership between Toronto Public Health , Unity Health Toronto and University Health Network , with all of us working together in response to the ongoing drug poisoning crisis . '' | `` As one of our four projects with OBIO , the partnership with Gray Oncology Solutions Inc. is an opportunity to use innovation to help elevate and streamline how we deliver care to our patients . '' | ||
Sources | 5 | 1 | 1 |
University Health Network Team
9 Team Members
University Health Network has 9 team members, including current Executive Vice President, Rebecca Repa.
Name | Work History | Title | Status |
---|---|---|---|
Rebecca Repa | Executive Vice President | Current | |
Name | Rebecca Repa | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Executive Vice President | ||||
Status | Current |